In select LAM patients with moderate-to-severe lung disease or rapid progression, treatment with an mTOR inhibitor may be used to stabilize or improve pulmonary function, quality of life, and functional performance.8,13–15 (Category 1). Here, MTOR is linked to lymphangioleiomyomatosis.